Jonathan Luu

<u>jluu@g.harvard.edu</u> • 408-889-3972 • Boston, MA • <u>www.jonathanluu.com</u>

Education

| Harvard University, Graduate School of Arts and Sciences PhD, Biostatistics | Boston, MA May 2024 |
|--|-----------------------------|
| University of Southern California, Keck School of Medicine MS, Biostatistics | Los Angeles, CA May 2019 |
| University of Southern California, Viterbi School of Engineering BS, Computer Science & Computer Engineering | Los Angeles, CA May 2017 |
| Research Experience | |
| Expanding the two-part model for clustered semi-continuous data | 2023 |
| • Developed Bayesian model to efficiently analyze cost and healthcare utilization data in nursing h | iomes |
| Applied model and metrics to Medicare data consisting of 20 million nursing home residents | |
| Addressing incomplete and missing electronic health records data in implementation science | 2022 |
| Characterized and quantified missing data in EHR databases maintained by community health ce | nters |
| HaSET program: Analyzing stunting of newborns in Ethiopia | 2022 |
| Analyzed data with significant measurement error to approximate prevalence of stunting in Ethic | • |
| Duration of viral shedding and culture positivity with post-vaccination breakthrough delta variant infecti | |
| Collected viral load and culture samples from MGH employees who tested positive for SARS-Co | oV-2 |
| Performed survival analysis and a spline predictive analysis on the data | |
| Estimating the treatment effect in randomized trials with correlated time-to-event outcomes | 2020 |
| • Simulated and compared three analysis methods for cluster randomized clinical trials | |
| LOFT-HF sample size re-estimation | 2020 |
| Re-estimated sample size for the LOFT-HF trial using blinded aggregate data | |
| A phase I/II study of E7389 Halichondrin B analog in metastatic urothelial tract cancer and renal insuffic | - |
| • Produced Kaplan-Meier plots, response and toxicity tables, and baseline statistics for DSMC rep | ort |
| Analyzed data using multivariate Cox regression for progression-free and overall survival | 2010 |
| A simulation evaluation of the effectiveness and usability of the 3+3 design for phase I clinical trials | 2019 |
| • Compared the 3+3 algorithm for phase I RCTs with more sophisticated methods through simulat | ion |
| Work Experience | |
| Intern: Bristol Myers Squibb | 2023 |
| Explored correlation between surrogate endpoints and overall survival in cancer trials | |
| Ran models stratified by indication and treatment type to quantify correlated relationship further | |
| Research Assistant: Boston College | 2023 |
| • Ran multiple-period cluster-randomized crossover trial to test the effectiveness of motivational interviewing and | |
| behavioral health services on COVID-19 vaccine uptake among Latinx adults | |
| Research Assistant: Enguidanos Labs | 2018 |
| Monitored REDCap database to collect data for a palliative care trial comparing home-based vs. hospital-based | |
| palliative care | |
| Presented demographics, ineligibility criteria, and patient concerns to funding agencies | |
| Teaching Experience | |
| Teaching Assistant | |
| Applied Survival Analysis (BST223) | 2021-2023 |
| Intro to Data Science (BST260), Survival Methods in Clinical Research (BST224) | 2020-2022 |
| Biostatistics Consulting Center | 2021-2022 |
| Consulted clients on study design, analysis planning, and programming | |
| StatStart | 2021-2023 |
| • Taught R programming and basic statistics to high school students through a summer project | |